About
Technology
Issues
FAQ
Links
Official Page
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.